PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 2026European Stroke Journal0 citationsOpen Access

Abstract Number: Esoc2026a1617 Predictors of Poor Functional Outcome in Patients With Medium Vessel Occlusions

View Full Paper
ABAnderson BritoEKEric KontowiczWHWilliam Haselden

Key Points

  • The study aims to predict 90-day functional outcomes in patients with medium vessel occlusions (MeVOs) to identify high-risk individuals.
  • Conducted a retrospective cohort study using a dual-center database of patients with primary MeVOs from January 2022 to May 2025.
  • Identified predictors using LASSO regression with a definition of poor functional outcome as mRS 3-6.
  • Included a total of 296 patients, analyzing age, NIHSS, Tmax, CBF, hypertension history, and IV thrombolysis usage.
  • Age was identified as a significant predictor of poor functional outcome (aOR: 1.05, 95% CI: 1.02-1.08, p<0.001).
  • EVT showed positive effects only in patients younger than 69 years, highlighting a critical age interaction (p=0.022).
  • 74.5% of patients underwent EVT, with 22.3% receiving medical management.

Abstract

Abstract Background and aims Recent randomized trials suggest that endovascular therapy (EVT) may not provide a significant benefit to patients with medium vessel occlusions (MeVOs). We aimed to develop a model to predict 90-day functional outcomes in patients with MeVOs to better recognize those at high-risk. Methods We conducted a retrospective cohort study using a prospective dual-center database of consecutive patients with primary MeVOs (distal or non-dominant M2, M3, A2-A3, P1-P2) who underwent EVT or medical management (MM) between January 2022 and May 2025. Predictors were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) regression. Poor functional outcome was defined as mRS 3-6. Interaction plots were examined to identify clinically meaningful cutpoints. Results A total of 296 patients (median age: 77, IQR: 68-84.2; 56.3% males) were included. Among them, 77.7% (N=230) underwent EVT, and 22.3% (N=66) received MM. The final model selected age, admission NIHSS, Tmax10s, CBF 30%, history of hypertension, and use of IV thrombolysis as predictors of poor functional outcome at 90-days. In this model, increasing age was associated with poor functional outcome (aOR: 1.05 95%CI: 1.02-1.08; p=0.001). Furthermore, we identified a significant interaction between EVT and age (p=0.022; Figure 1). When stratifying the cohort by age, we observed that EVT has a positive effect only in younger patients (69 years) (Figure 2). Conclusions Our study suggests a clear differential benefit of EVT in patients with MeVOs who are younger than 69 years.This finding is crucial for stratifying higher-risk patients and informing selection criteria for future MEVOs studies. Conflict of interest Santiago Ortega-Gutierrez received grants from NIH-NINDS (R01NS127114, R01NS138765, R03NS126804), PCORI, Stryker, Medtronic, and Methinks. Marc Ribo is the Chief Medical Office of Methinks and has equity interests. Anderson Brito and the rest of the team have nothing to disclose. Figure 1 - belongs to Results Figure 2 - belongs to Results

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Brito et al. (2026) studied this question.

synapsesocial.com/papers/69fd7fb8bfa21ec5bbf0845chttps://doi.org/10.1093/esj/aakag023.771
Ask AI
Helpful
Bookmark
Share
View Full Paper